Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Codice etico e Modello 231

Philogen to attend the International Mass Spectrometry Congress 2022 in Maastricht (August 27th-September 2nd, 2022)

Jul 6, 2022 | 2022, Events

Dr. Ettore Gilardoni, Head of Bio-MS at Philogen, will present a poster entitled: A mass spectrometry-based method for the determination of in vivo biodistribution of small molecule-metal conjugates. Dr. Gilardoni will also give a presentation on August 31st,...

Philogen to attend the 13th World ADC San Diego 2022, San Diego, USA (6-9 September 2022)

Jun 27, 2022 | 2022, Events, Scientific

Philogen will attend the 13th World ADC in San Diego (USA) in September 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture in person entitled “Pan-Tumoral Small Molecule-Drug Conjugates Targeting Fibroblasts Activation...

Philogen to attend EANO Congress in Vienna, Austria (15-18 September 2022)

Jun 27, 2022 | 2022, Events

Philogen will attend EANO Meeting in Vienna in September 2022. More details on the lecture held by Philogen will follow shortly. Please visit the EANO Meeting Website for additional information.

Philogen to attend the Peptide Therapeutic Forum 2022 on August 25-26, 2022

Mar 15, 2022 | 2022, Events

Philogen announces its attendance at the Peptide Therapeutic Forum 2022. Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled “Small Molecule Therapeutics as an alternative to Peptide Therapeutics: a clean strategy to...

Philogen to attend the PEGS Europe 2022 on November 14-16, 2022

Mar 15, 2022 | 2022, Events

Dario Neri, co-founder, CEO and CSO, is giving a lecture entitled “Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications”. Dario Neri is giving a talk on “intra-cork” strategies to enhance the...

Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)

Mar 15, 2022 | 2022, Events

Philogen will attend the TIDES Europe in Vienna in November 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture entitled “Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast...

Recent Posts

  • 08 Agosto 2022 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma
  • 25 luglio 2022 – Aggiornamento sul programma di acquisto di azioni proprie
  • 18 luglio 2022 – Aggiornamento sul programma di acquisto di azioni proprie
  • 11 luglio 2022 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it